Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines
BLADDER CANCER ADVOCACY NETWORK
Friday, June 02, 2017
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center and BCAN Scientific Advisor, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.
The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.